Revolution Medicines RVMD 深 滬
已收盤 05-08 16:00:00 美东时间
141.81
-0.700
-0.49%
華盛通- 最 高144.61
- 今 開142.56
- 成交量 251.44万股
- 最 低 140.53
- 昨 收 142.51
- 總市值 301.48亿
- 52周最高 155.70
- 市盈率 靜 --
- 換手率 1.18%
- 52周最低 34.00
- 委 比 -99.78%
- 總股本 2.13亿
- 歷史最高 155.70
- 量 比 0.87
- 振 幅 2.86%
- 歷史最低 14.08
- 每 手 1
- 風險率 33.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $183
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $186 to $183.
05-07 18:50
财报速睇 | Revolution Medicines 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损4.54亿美元，同比亏损扩大112.6%
华盛资讯5月7日讯，Revolution Medicines公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损4.54亿美元，同比亏损扩大112.6%。
05-07 10:17
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.82) by 25.82 percent. This is a 102.65 percent decrease over losses of $(1.13) per
05-07 04:03
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Royalty Pharma (NASDAQ:RPRX) held its first-quarter earnings conference call on...
05-06 21:56
FDA授权提前使用Revolution胰腺癌药物
美国食品药品监督管理局5月1日宣布，授权在临床试验之外提前使用Revolution Medicines公司研发的实验性胰腺癌药物daraxonrasib。这...
05-02 02:46
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug
05-01 23:51
'F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer' - New York Times
https://www.nytimes.com/2026/05/01/business/fda-pancreatic-cancer-drug.html
05-01 23:45
